Sudan Loganathan
Stock Analyst at Stephens
(4.26)
# 1,403
Out of 4,501 analysts
38
Total ratings
64.7%
Success rate
24.2%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.29 | +287.60% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $144.76 | +51.98% | 1 | May 11, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgraded: Hold | $40 → $32 | $31.47 | +1.68% | 3 | May 7, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $23.35 | +28.48% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $110 → $100 | $119.35 | -16.21% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Maintained: Buy | $15 → $18 | $8.27 | +117.65% | 4 | Feb 25, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Buy | $95 | $133.65 | -28.92% | 1 | Dec 17, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $13 → $8 | $2.67 | +199.63% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $9.49 | +58.06% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $4.06 | +47.78% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $35 | $36.16 | n/a | 2 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 → $60 | $56.50 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $30 | $23.06 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $0.93 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $10.49 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $36.99 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $4.41 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $13.01 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.29
Upside: +287.60%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $144.76
Upside: +51.98%
Catalyst Pharmaceuticals
May 7, 2026
Downgraded: Hold
Price Target: $40 → $32
Current: $31.47
Upside: +1.68%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $23.35
Upside: +28.48%
Kymera Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: $110 → $100
Current: $119.35
Upside: -16.21%
Arvinas
Feb 25, 2026
Maintained: Buy
Price Target: $15 → $18
Current: $8.27
Upside: +117.65%
Apogee Therapeutics
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $95
Current: $133.65
Upside: -28.92%
Pyxis Oncology
Nov 24, 2025
Maintained: Buy
Price Target: $13 → $8
Current: $2.67
Upside: +199.63%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $9.49
Upside: +58.06%
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $4.06
Upside: +47.78%
Jun 30, 2025
Maintained: Buy
Price Target: $5 → $35
Current: $36.16
Upside: n/a
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $56.50
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $20 → $30
Current: $23.06
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $0.93
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $10.49
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $36.99
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $4.41
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $13.01
Upside: n/a